Clinical trial

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

NCT06287463

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2024-05-14

PhasePHASE1

Study timeline

Study start (actual)2024-05-14Date precision: day

Registry last updated2026-03-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Solid Tumorunresolved

RAF Mutationunresolved

RAS Mutationunresolved

NF1 Mutationunresolved

Non-Small Cell Lung Cancerunresolved

Pancreatic Ductal Adenocarcinomaunresolved

Melanomaunresolved

BRAF Gene Mutationunresolved

CRAF Gene Mutationunresolved

Castration-Resistant Prostate Cancer (CRPC)unresolved

Interventions

Sponsors & collaborators

Deciphera Pharmaceuticals, LLClead sponsor

Mapped research locations

BostonMassachusetts, United States1 Los AngelesCalifornia, United States1 San AntonioTexas, United States1 NashvilleTennessee, United States1 San FranciscoCalifornia, United States1 OrlandoFlorida, United States1 DenverColorado, United States1 BuffaloNew York, United States1 FairfaxVirginia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06287463 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.